tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksTipRanks Momentum IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Smart Growth
New
Research Tools
Trending StocksCompare StocksCompare ETFsMost Visited Websites
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News WireArrivedEquityMultiple
Follow Us
TOOLS
News
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Notification Center
Top ETFs
Top Smart Score Stocks
Popular
Earnings
Plans & Pricing
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
TipRanks Momentum Index
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Trending Stocks
Compare Stocks
Compare ETFs
Most Visited Websites
Daily Feeds
Daily Analyst Ratings
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Class Actions
Class Actions
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us

Hutchmed announces NMPA approval for Orpathys supplemental new drug application
The FlyHutchmed announces NMPA approval for Orpathys supplemental new drug application
6d ago
HCM
HUTCHMED’s ORPATHYS® Receives Full NMPA Approval for Expanded NSCLC Treatment
PremiumCompany Announcements
HUTCHMED’s ORPATHYS® Receives Full NMPA Approval for Expanded NSCLC Treatment
6d ago
Hutchmed price target lowered to $26 from $30 at BofA
PremiumThe Fly
Hutchmed price target lowered to $26 from $30 at BofA
13d ago
HCM
Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
PremiumThe Fly
Morning Movers: Neumora Therapeutics plummets after KOASTAL-1 misses endpoint
18d ago
HCM
MCD
HUTCHMED’s Lung Cancer Drug Combo Gains Priority Review
PremiumCompany Announcements
HUTCHMED’s Lung Cancer Drug Combo Gains Priority Review
19d ago
Hutchmed announces NDA acceptance in China, payment from AstraZeneca
PremiumThe FlyHutchmed announces NDA acceptance in China, payment from AstraZeneca
19d ago
AZN
HCM
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
Premium
The Fly
Hutchmed divests 45% interest in Shanghai Hutchison for $608M
19d ago
HCM
HUTCHMED Sells Major Stake to Focus on Core Business
Premium
Company Announcements
HUTCHMED Sells Major Stake to Focus on Core Business
19d ago
HUTCHMED Expands Brokerage Partnerships in London
PremiumCompany Announcements
HUTCHMED Expands Brokerage Partnerships in London
20d ago
HUTCHMED’s Share Option Scheme Update and Stock Issuance
PremiumCompany Announcements
HUTCHMED’s Share Option Scheme Update and Stock Issuance
21d ago
HUTCHMED Secures Milestone with Takeda Partnership
PremiumCompany Announcements
HUTCHMED Secures Milestone with Takeda Partnership
1M ago
Hutchmed to receive milestone payment from Takeda
PremiumThe Fly
Hutchmed to receive milestone payment from Takeda
1M ago
HCM
TAK
Hutchmed announces BTD in China for Orpathys, Tagrisso combination
PremiumThe FlyHutchmed announces BTD in China for Orpathys, Tagrisso combination
1M ago
HCM
HUTCHMED’s Lung Cancer Therapy Gains Breakthrough Status
Premium
Company Announcements
HUTCHMED’s Lung Cancer Therapy Gains Breakthrough Status
1M ago
Hutchmed announces Elunate, Tyvyt NDA granted approval in China
Premium
The Fly
Hutchmed announces Elunate, Tyvyt NDA granted approval in China
2M ago
HCM
HUTCHMED Gains Approval for Innovative Cancer Therapy
PremiumCompany Announcements
HUTCHMED Gains Approval for Innovative Cancer Therapy
2M ago
HUTCHMED Announces Share Capital Details
PremiumCompany Announcements
HUTCHMED Announces Share Capital Details
2M ago
HUTCHMED Secures Continued Drug Reimbursement for ORPATHYS®
PremiumCompany Announcements
HUTCHMED Secures Continued Drug Reimbursement for ORPATHYS®
2M ago
Hutchmed to receive milestone payment following Takeda launch of Fruzaqla
PremiumThe Fly
Hutchmed to receive milestone payment following Takeda launch of Fruzaqla
2M ago
HCM
TAK
HUTCHMED Expands Cancer Treatment Market with Japan Launch
PremiumCompany AnnouncementsHUTCHMED Expands Cancer Treatment Market with Japan Launch
2M ago
HUTCHMED China Announces Diverse Board Leadership
Premium
Company Announcements
HUTCHMED China Announces Diverse Board Leadership
2M ago
HUTCHMED Appoints Experienced Director to Board
Premium
Company Announcements
HUTCHMED Appoints Experienced Director to Board
2M ago

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >